Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists

Journal of Microencapsulation

Volumn 24, Issue 8, 2007, Pages 715-730

  Bouligand, Jerome ^a,b   Couvreur, Patrick ^a   Layre, Anne ^a   Deroussent, Alain ^b   Paci, Angelo ^b   Delain, Etienne ^b   Vassal, Gilles ^b   Gref, Ruxandra ^a  

^a CNRS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Busulfan; Characterization; Crystallization; Emulsion solvent evaporation; Long circulating nanospheres; Nanoprecipitation

Indexed keywords

BUSULFAN; COPOLYMER; MACROGOL; NANOSPHERE; POLYESTER; SOLVENT;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COATING; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; EVAPORATION; GAS CHROMATOGRAPHY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; LIGHT SCATTERING; MASS SPECTROMETRY; MOLECULAR INTERACTION; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; SOLVENT EFFECT; TRANSMISSION ELECTRON MICROSCOPY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CALORIMETRY, DIFFERENTIAL SCANNING; DELAYED-ACTION PREPARATIONS; HEPATIC VENO-OCCLUSIVE DISEASE; NANOCAPSULES; NANOSPHERES; POLYETHYLENE GLYCOLS;

EID: 35248812886     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/02652040701500905     Document Type: Article

References (45)

1. Andersson, BS, Kashyap, A., Couriel, D., Madden, T., de Lima, M., Thall, PF, Fernandez, H., Vaughan, WP, Jones, R., Wingard, JR, Blume, KG and Champlin, RE (2003) Intravenous busulfan in pretransplant chemotherapy: Bioavailability and patient benefit. Biology of Blood Marrow Transplantation, 9, pp. 722-724.
2. Bazile, D., Prud'homme, C., Bassoullet, MT, Marlard, M., Spenlehauer, G. and Veillard, M. (1995) Stealth Me.PEG-PLA nanoparticules avoid uptake by the mononuclear phagocytes system. Journal of Pharmaceutical Sciences, 84, pp. 493-498.
3. Bedford, P. and Fox, BW (1982) Repair of DNA interstrand crosslinks after busulphan. A possible mode of resistance. Cancer, Chemotherapy and Pharmacology, 8, pp. 3-7.
4. Bhagwatwar, HP, Phadungpojna, S., Chow, DS and Andersson, BS (1996) Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer, Chemotherapy and Pharmacology, 37, pp. 401-408.
5. Bouligand, J., Boland, I., Valteau-Couanet, D., Deroussent, A., Kalifa, C., Hartmann, O. and Vassal, G. (2003) In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplantation, 32, pp. 979-986.
6. Bouligand, J., Paci, A., Mercier, L., Vassal, G. and Bourget, P. (2004) High-performance thin-layer chromatography with a derivatization procedure, a suitable method for the identification and the quantitation of busulfan in various pharmaceutical products. Journal of Pharmaceutics and Biomedicine Analysis, 34, pp. 525-530.
7. Cattel, L., Ceruti, M. and Dosio, F. (2003) From conventional to stealth liposomes: A new frontier in cancer chemotherapy. Tumori, 89, pp. 237-249.
8. Chow, AHL, Chow, PKK, Zhuang, J. and Groen, AK (1985) Modification of acetaminophen crystals: Influence of growth in aqueous solutions containig of growth in aqueous solutions containig p-acetoxyacetanilide on crystal properties. International Journal of Pharmaceutics, 24, pp. 239-258.
9. Chow, KY, Mehdizadeh, M. and Groen, AK (1984) Modification of adipic crystals: Influence of growth in the presence of fatty acid additives on crystals properties. International Journal of Pharmaceutics, 20, pp. 3-24.
10. Dalle, JH, Wall, D., Theoret, Y., Duval, M., Shaw, L., Larocque, D., Taylor, C., Gardiner, J., Vachon, MF and Champagne, MA (2003) Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: Clinical and pharmacokinetic results. Bone Marrow Transplantation, 32, pp. 647-651.
11. DeLeve, LD and Wang, X. (2000) Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology, 60, pp. 143-154.
12. Dunn, CD (1974) The chemical and biological properties of busulphan ('Myleran'). Experimental Hematology, 2, pp. 101-117.
13. Ehrsson, H. and Hassan, M. (1986) Degradation of busulfan in aqueous solution. Journal of Pharmaceutics and Biomedical Analysis, 4, pp. 95-101.
14. Ghermani, NE, Bire, A Spasojevic-de, Bouhmaida, N., Ouharzoune, S., Bouligand, J., Layre, A., Gref, R. and Couvreur, P. (2004) Molecular reactivity of busulfan through its experimental electrostatic properties in the solid state. Pharmaceutical Research, 21, pp. 598-607.
15. Gref, R., Domb, A., Quellec, P., Blunk, T., Muller, RH, Verbavatz, JM and Langer, R. (1995) The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Advanced Drug Delivery Reviews, 16, pp. 215-233.
16. Gref, R., Luck, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T. and Muller, RH (2000) 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids and Surfactants B: Biointerfaces, 18, pp. 301-313.
17. Gref, R., Minamitake, Y., Peracchia, MT, Trubetskoy, V., Torchilin, V. and Langer, R. (1994) Biodegradable long-circulating polymeric nanospheres. Science, 263, pp. 1600-1603.
18. Grover, PK, Moritz, RL, Simpson, RJ and Ryall, RL (1998) Inhibition of growth and aggregation of calcium oxalate crystals in vitro - a comparison of four human proteins. European Journal of Biochemistry, 253, pp. 637-644.
19. Hartmann, O., Benhamou, E., Beaujean, F., Pico, JL, Kalifa, C., Patte, C., Flamant, F. and Lemerle, J. (1986) High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A phase II study. Journal of Clinical Oncology, 4, pp. 1804-1810.
20. Hassan, M., Ehrsson, H. and Ljungman, P. (1996) Aspects concerning busulfan pharmacokinetics and bioavailability. Leukemia and Lymphoma, 22, pp. 395-407.
21. Hassan, M., Hassan, Z., Nilsson, C., Rehim, MA, Kumlien, S., Elfsson, B. and Kallberg, N. (1998) Pharmacokinetics and distribution of liposomal busulfan in the rat: A new formulation for intravenous administration. Cancer, Chemotherapy and Pharmacology, 42, pp. 471-478.
22. Hassan, M., Ljungman, P., Bolme, P., Ringden, O., Syruckova, Z., Bekassy, A., Stary, J., Wallin, I. and Kallberg, N. (1994) Busulfan bioavailability. Blood, 84, pp. 2144-2150.
23. Hassan, M., Nilsson, C., Hassan, Z., Gungor, T., Aschan, J., Winiarski, J., Hentschke, P., Ringden, O., Eber, S., Seger, R. and Ljungman, P. (2002) A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Bone Marrow Transplantation, 30, pp. 833-841.
24. Hassan, Z., Ljungman, P., Ringden, O., Winiarski, J., Nilsson, C., Aschan, J., Whitley, HR and Hassan, M. (2001) Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplantation, 27, pp. 479-485.
25. Hassan, Z., Nilsson, C. and Hassan, M. (1998) Liposomal busulphan: bioavailability and effect on bone marrow in mice. Bone Marrow Transplantation, 22, pp. 913-918.
26. Kashyap, A., Wingard, J., Cagnoni, P., Roy, J., Tarantolo, S., Blume, K., Niland, J., Palmer, JM and Vaughan, W. (2002) Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biology of Blood Marrow Transplantation, 8, pp. 493-500.
27. Layre, A., Couvreur, P., Chacun, H., Richard, J., Passirani, C., Requier, D., Benoit, JP and Gref, R. (2006) Novel composite core-shell nanoparticles as busulfan carriers. Journal of Controlled Release, 111, pp. 271-280.
28. Layre, AM, Couvreur, P., Chacun, H., Aymes-Chodur, C., Ghermani, NE, Poupaert, J., Richard, J., Requier, D. and Gref, R. (2006) Busulfan loading into poly(alkyl cyanoacrylate) nanoparticles: Physico-chemistry and molecular modeling. Journal of Biomedical Materials Research B: Applied Biomaterials, 79, pp. 254-262.
29. Layre, AM, Gref, R., Richard, J., Requier, D., Chacun, H., Appel, M., Domb, AJ and Couvreur, P. (2005) Nanoencapsulation of a crystalline drug. International. Journal of Pharmaceutics, 298, pp. 323-327.
30. McDonald, GB, Hinds, MS, Fisher, LD, Schoch, HG, Wolford, JL, Banaji, M., Hardin, BJ, Shulman, HM and Clift, RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Annals of Internal Medicine, 118, pp. 255-267.
31. Meresse, V., Hartmann, O., Vassal, G., Benhamou, E., Valteau-Couanet, D., Brugieres, L. and Lemerle, J. (1992) Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplantation, 10, pp. 135-141.
32. Montet, JC, Parquet, M., Sacquet, E., Montet, AM, Infante, R. and Amic, J. (1987) beta-Muricholic acid; potentiometric and cholesterol-dissolving properties. Biochimica et Biophysica Acta, 918, pp. 1-10.
33. Nguyen, L., Fuller, D., Lennon, S., Leger, F. and Puozzo, C. (2004) I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplantation, 33, pp. 979-987.
34. Nikolakakis, I., Kachrimanis, K. and Malamataris, S. (2000) Relations between crystallisation conditions and micromeritic properties of ibuprofen. International Journal of Pharmaceutics, 201, pp. 79-88.
35. Olavarria, E., Hassan, M., Eades, A., Nilsson, C., Timms, A., Matthews, J., Craddock, C., Kanfer, E., Apperley, J. and Goldman, J. (2000) A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation [In Process Citation]. Leukemia, 14, pp. 1954-1959.
36. Raghavan, SL, Trividic, A., Davis, AF and Hadgraft, J. (2001) Crystallization of hydrocortisone acetate: Influence of polymers. International Journal of Pharmaceutics, 212, pp. 213-221.
37. Santos, GW (1993) The development of busulfan/cyclophosphamide preparative regimens. Seminars in Oncology, 20, pp. 12-16.
38. Schott, H. and Royce, AE (1985) Effect of nonionic surfactants on aqueous primidone suspensions. Journal of Pharmaceutical Sciences, 74, pp. 957-962.
39. Schuler, US, Ehrsam, M., Schneider, A., Schmidt, H., Deeg, J. and Ehninger, G. (1998) Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplantation, 22, pp. 241-244.
40. Schuler, US, Renner, UD, Kroschinsky, F., Johne, C., Jenke, A., Naumann, R., Bornhauser, M., Deeg, HJ and Ehninger, G. (2001) Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. British Journal of Haematology, 114, pp. 944-950.
41. Shirane, Y., Kurokawa, Y., Miyashita, S., Komatsu, H. and Kagawa, S. (1999) Study of inhibition mechanisms of glycosaminoglycans on calcium oxalate monohydrate crystals by atomic force microscopy. Urology Research, 27, pp. 426-431.
42. Tazuma, S., Sasaki, H., Mizuno, S., Sagawa, H., Hashiba, S., Horiuchi, I. and Kajiyama, G. (1989) Effect of ursodeoxycholic acid administration on nucleation time in human gallbladder bile. Gastroenterology, 97, pp. 173-178.
43. Usui, F., Maeda, K., Kusai, A., Nishimura, K. and Yamamoto, K. (1997) Inhibitory effects of water-soluble polymers on precipitation of RS-8359. International Journal of Pharmaceutics, 154, pp. 59-66.
44. Vassal, G. and Gouyette, A. (1988) Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. Journal of Chromatography, 428, pp. 357-361.
45. Westerhof, GR, Ploemacher, RE, Boudewijn, A., Blokland, I., Dillingh, JH, McGown, AT, Hadfield, JA, Dawson, MJ and Down, JD (2000) Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Research, 60, pp. 5470-5478.